Skip to Main Content

Author Details

Philip E Lammers
Baptist Cancer Center
2013
30
19
PMIDPaper TitleJournal TitlePublished Year
35216901The reckoning: The return of genomic results to 1444 participants across the eMERGE3 Network.Genet Med2022
33389527Increased ease of access to genetic counseling for low-income women with breast cancer using a point of care screening tool.J Community Genet2021
33746047Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.Ann Oncol2021
34590046Survival Impact of an Enhanced Multidisciplinary Thoracic Oncology Conference in a Regional Community Health Care System.JTO Clin Res Rep2021
34405547Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.Cancer Med2021
34814868Enhancing Cancer care of rural dwellers through telehealth and engagement (ENCORE): protocol to evaluate effectiveness of a multi-level telehealth-based intervention to improve rural cancer care delivery.BMC Cancer2021
32349224Returning Results in the Genomic Era: Initial Experiences of the eMERGE Network.J Pers Med2020
32669677Participant choices for return of genomic results in the eMERGE Network.Genet Med2020
30770546Bispecific Antibodies in the Treatment of Hematologic Malignancies.Clin Pharmacol Ther2019
31486832Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.JAMA Oncol2019
30060600Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes.Int J Mol Sci2018
30002437Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer.Br J Cancer2018
29861863High salt induces P-glycoprotein mediated treatment resistance in breast cancer cells through store operated calcium influx.Oncotarget2018
30179249Extracellular histones are the ligands for the uptake of exosomes and hydroxyapatite-nanoparticles by tumor cells via syndecan-4.FEBS Lett2018
29849799A rapidly growing human papillomavirus-positive oral tongue squamous cell carcinoma in a 21-year old female: A case report.Oncol Lett2018
29057243Smoking, depression, and hospital costs of respiratory cancers: Examining race and sex variation.Fam Med Community Health2017
28134851Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey.Pharmaceuticals (Basel)2017
28236776Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.Breast2017
26906106Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma.Clin Lymphoma Myeloma Leuk2016
27882696Fetuin-A (alpha 2HS glycoprotein) modulates growth, motility, invasion, and senescence in high-grade astrocytomas.Cancer Med2016
27554763Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis.Cancer Prev Res (Phila)2016
25918285Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing.J Clin Oncol2015
26301800Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis.J Thorac Oncol2015
26903777Biosimilars: Extrapolating the evidence. A roundtable discussion.EJC Suppl2015
25845992nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer.Oncologist2015
24453288A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.J Natl Compr Canc Netw2014
25232798Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets.Pharmaceuticals (Basel)2014
24736081Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer.J Thorac Oncol2014
24267729A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer.Clin Breast Cancer2013
24142825Targeting angiogenesis in advanced non-small cell lung cancer.J Natl Compr Canc Netw2013
  • 1 - 30 of 30

Recommended Authors

Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Career Start Year 2012
Number of shared co-authors 1
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 0
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 2
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 0
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 2
Seoul National University Hospital
Career Start Year 2006
Number of shared co-authors 2
David Geffen School of Medicine, University of California Los Angeles
Career Start Year 2005
Number of shared co-authors 0
The Ottawa Hospital Research Institute
Career Start Year 2005
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 0
Massachusetts General Hospital Cancer Center
Career Start Year 2004
Number of shared co-authors 2
University of California san francisco
Career Start Year 2003
Number of shared co-authors 0
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 3
The University of Manchester
Career Start Year 2000
Number of shared co-authors 2
Washington University School of Medicine
Career Start Year 2000
Number of shared co-authors 1
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 4
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 1
University of California Davis Comprehensive Cancer Center
Career Start Year 1996
Number of shared co-authors 1
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 2
University of British Columbia
Career Start Year 1995
Number of shared co-authors 0
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 0
Injury Prevention Research Center, University of North Carolina
Career Start Year 1994
Number of shared co-authors 2
Memorial Sloan Kettering Cancer Center
Career Start Year 1994
Number of shared co-authors 2
Olivia Newton-John Cancer Research Institute
Career Start Year 1993
Number of shared co-authors 0
David Geffen School of Medicine at university of california los angeles
Career Start Year 1991
Number of shared co-authors 1
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 3
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 1
Dana-Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 12
Yale School of Medicine
Career Start Year 1984
Number of shared co-authors 3
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 1981
Number of shared co-authors 2
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 0

Collaborators

Biomedical Ethics, Mayo Clinic and Foundation
Co-authored papers 3
Harvard Medical School
Co-authored papers 3
Center for Applied Genomics, Children's Hospital of Philadelphia
Co-authored papers 3
Northwestern University, Center for Genetic Medicine
Co-authored papers 3
Vanderbilt Genetics Institute, Vanderbilt University Medical Center
Co-authored papers 3
Boston Children's Hospital, Harvard Medical School
Co-authored papers 3
Vagelos College of Physicians and Surgeons, Columbia University
Co-authored papers 3
Center for Genetic Medicine, Feinberg School of Medicine, Northwestern University
Co-authored papers 3
Mayo Clinic
Co-authored papers 3
Cincinnati Children's Hospital Medical Center
Co-authored papers 3
Northwestern University, Center for Genetic Medicine
Co-authored papers 3
Kaiser Permanente Washington
Co-authored papers 3
Harvard Medical School, Vanderbilt University, Yale University Yale Law School
Co-authored papers 2
Harvard Medical School, Harvard Pilgrim Health Care Institute
Co-authored papers 2
Meharry Medical College
Co-authored papers 2
Kaiser Permanente Washington Health Research Institute
Co-authored papers 2
Center for Law, Columbia University Irving Medical Center
Co-authored papers 2
National Institutes of Health
Co-authored papers 2
Brigham and Women's Hospital, Broad Institute Ariadne Labs and Harvard Medical School
Co-authored papers 2
City of Hope National Medical Center
Co-authored papers 2
Cincinnati Children's Hospital Medical Center
Co-authored papers 2
Research Institute
Co-authored papers 2
University of Washington Medical Center
Co-authored papers 2
University of Washington.
Co-authored papers 2
Genomic Medicine Institute
Co-authored papers 2
Columbia University College of Physicians and Surgeons
Co-authored papers 2
Co-authored papers 2
Vanderbilt University Medical Center
Co-authored papers 2
Mayo Clinic
Co-authored papers 2
University of Washington
Co-authored papers 2